Table 4.
Examples of delivery methods used for in vivo miRNA delivery.
| Delivery Method | miRNA | Disease | Route of Administration | Disease Model | Refs. |
|---|---|---|---|---|---|
| Inorganic NPs | |||||
| Gold Iron Oxide NPs | anti-miR-21 miR-100 |
Glioblastoma | Intranasal | U87-MG GBM cell-derived orthotopic mice xenograft | [47] |
| GD2 antibody targeted coated silica NPs | miR-34a | Neuroblastoma | Intravenous | NB1691luc and SK-N-ASluc orthotopic xenograft |
[44] |
| Lipid-based NPs | |||||
| LNPs (DODMA/DOTAP/DOPC/CHOL/mPEG-DPPE) |
anti-miR-21 | Lung cancer | Intravenous | A549 mouse xenograft | [65] |
| SLNs (DDBA/Glyceryl monostearate/Soy phosphatidylcho-line/CHOL) |
miR-34a | Lung cancer | Intravenous | in situ murine lung metastasis | [70] |
| Polymeric NPs | |||||
| uPAR targeted PLGA NPs | anti-miR-10b anti-miR-21 |
Breast cancer | Intravenous | TNBC xenograft | [91] |
| HA-CS targeted NPs | miR-34a | Breast cancer | Intratumoral | MDA-MB-231 mice xenograft | [113] |
Abbreviations: GD2: disialoganglioside; uPAR: urokinase plasminogen activator receptor; PLGA: polylactic-co-glycolic acid; HA: Hyaluronic acid; CS: chitosan; GBM: glioblastoma multiforme; TNBC: triple negative breast cancer.